The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.

The latest price target for Biodesix (NASDAQ: BDSX) was reported by Morgan Stanley on May 12, 2022. The analyst firm set a price target for $5.00 expecting BDSX to rise to within 12 months (a possible 237.84% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Biodesix (NASDAQ: BDSX) was provided by Morgan Stanley, and Biodesix maintained their equal-weight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biodesix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biodesix was filed on May 12, 2022 so you should expect the next rating to be made available sometime around May 12, 2023.

While ratings are subjective and will change, the latest Biodesix (BDSX) rating was a maintained with a price target of $7.00 to $5.00. The current price Biodesix (BDSX) is trading at is $1.48, which is out of the analyst’s predicted range.